Global Innovative Platforms completed a Reg A offering and submitted a 15c2-11 application to FINRA while expanding scientific development across multiple parasitic infection detection signatures. The company reported $136,500 in revenue for H1 2026 and maintains sufficient capital through year-end, positioning itself toward commercialization of its breath-based veterinary diagnostic platform.